Alnylam Pharmaceuticals, Inc. has announced that its research on therapeutic silencing of microRNAs was featured in an article published in the March 16, 2006 issue of The New England Journal of Medicine.
The article titled 'MicroRNAs as Therapeutic Targets' was authored by Dr. Michael Czech, Chair of the Program in Molecular Medicine at the University of Massachusetts Medical School, and discussed clinical applications for intervening with microRNAs.
Research by Alnylam and its collaborators at The Rockefeller University has demonstrated that miRNAs can be specifically silenced by using antagomirs, a class of oligonucleotide drugs.
Alnylam believes this approach creates the opportunity to design antagomirs that target miRNAs involved in the cause or pathway of human diseases, such as cancer and viral infection.
"We're thrilled to have the importance of miRNAs and Alnylam's own work in this field recognized and reviewed in one of the world's leading medical journals," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam.
"We believe that the opportunity to target miRNAs involved in human disease with antagomirs is an important extension of our platform to harness the RNAi pathway for discovery of innovative medicines."